Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anxiolytic Drugs: Benzodiazepines and Buspirone01:29

Anxiolytic Drugs: Benzodiazepines and Buspirone

3.0K
Benzodiazepines are a class of anxiolytic drugs known for their rapid efficacy and high therapeutic-to-lethal dose ratio, but with a potential risk of drug dependence. These drugs are lipophilic, allowing for rapid absorption after oral administration, eventually reaching the central nervous system (CNS). Once in the CNS, benzodiazepines bind to the allosteric site of the GABAA receptor. This binding enhances the inhibitory effects of the neurotransmitter GABA. By doing so, they prevent...
3.0K
Anxiolytic Drugs: Overview01:26

Anxiolytic Drugs: Overview

1.4K
Anxiolytic drugs are vital in managing anxiety disorders by effectively alleviating symptoms such as excessive fear, tachycardia, and tremors. There are several classes of anxiolytic medications, each with unique mechanisms of action and potential side effects.
Primary Types of Anxiolytic Drugs
1. Benzodiazepines:
Benzodiazepines bind to the GABA-A receptor in the brain, enhancing GABA's interaction. This action reduces neurotransmission, effectively blocking anxiety-associated limbic...
1.4K
CNS Depressants: Barbiturates and Benzodiazepines01:14

CNS Depressants: Barbiturates and Benzodiazepines

1.7K
CNS depressants include drugs from the category of barbiturates and benzodiazepines. They are valuable medications for managing anxiety disorders and insomnia. Barbiturates, once used to induce and maintain sleep, have been replaced mainly by benzodiazepines due to barbiturate's toxicity, tolerance, and overdose risks. They interact with GABAA receptors, leading to sedation at low doses and potentially coma and death at higher doses. Phenobarbital, a long-acting barbiturate, possesses...
1.7K
Sedatives and Hypnotics Drugs: Benzodiazepines01:19

Sedatives and Hypnotics Drugs: Benzodiazepines

1.2K
Benzodiazepines have both sedative and hypnotic properties. They include compounds such as diazepam (Valium) and alprazolam (Xanax). Structurally, their cores are similar, consisting of the fusion of a benzene ring and a diazepine ring, but they share a common mechanism of action in the central nervous system (CNS).
Benzodiazepines work by enhancing the effects of the inhibitory neurotransmitter GABA. They bind to the GABAA receptor, increasing its affinity for GABA, which opens chloride...
1.2K
Sedatives and Hypnotics Drugs: Barbiturates01:20

Sedatives and Hypnotics Drugs: Barbiturates

1.3K
Sedatives and hypnotics encompass a drug class that acts on the central nervous system (CNS) to alleviate anxiety, promote relaxation and induce sleep.These drugs function by amplifying the actions of the neurotransmitter γ-aminobutyric acid (GABA), resulting in reduced neuronal activity. Barbiturates, a subset of sedatives and hypnotics first synthesized in the late 1800s, are categorized into ultra-short, short, intermediate, and long-acting groups based on their duration of effect. A...
1.3K
Sedatives and Hypnotics: Overview01:23

Sedatives and Hypnotics: Overview

2.0K
Sedatives are drugs that alleviate anxiety, while hypnotics induce sleep. Both classes of medication suppress neuronal activity, leading to a calming effect for sedatives and facilitating sleep for hypnotics.
Sedative-hypnotics are categorized into barbiturates, benzodiazepines (BZDs), and non-benzodiazepines or Z-drugs. These drugs work by suppressing central nervous system activity, and this suppression is dose-dependent. Older sedative medications, like barbiturates, follow a linear curve in...
2.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Involving, Empowering, and Training End Users with Disabilities to Fully Participate in the Web Accessibility Directive Objectives First Results from the UPowerWAD Project.

Studies in health technology and informatics·2023
Same author

The Effects of Alcohol Use on Prospective Memory: A Systematic Literature Review.

Substance use & misuse·2021
Same author

Assessing the European impact of alcohol misuse and illicit drug dependence research: clinical practice guidelines and evidence-base policy.

Evidence-based mental health·2020
Same author

A review of the management of antidepressant discontinuation symptoms.

Therapeutic advances in psychopharmacology·2016
Same author

Usage of benzodiazepines: A review.

International journal of psychiatry in clinical practice·2014
Same author

Benzodiazepine harm: how can it be reduced?

British journal of clinical pharmacology·2012

Related Experiment Video

Updated: Mar 27, 2026

A Novel Method of Drug Administration to Multiple Zebrafish Danio rerio and the Quantification of Withdrawal
10:52

A Novel Method of Drug Administration to Multiple Zebrafish Danio rerio and the Quantification of Withdrawal

Published on: November 12, 2014

12.7K

Withdrawing Benzodiazepines in Patients With Anxiety Disorders.

Malcolm Lader1, Andri Kyriacou2

  • 1National Addiction Centre, Addictions Department, Institute of Psychiatry, Psychology and Neurosciences, King's College London, Denmark Hill, London, SE5 8AF, UK. malcolm.lader@kcl.ac.uk.

Current Psychiatry Reports
|January 7, 2016
PubMed
Summary

Long-term benzodiazepine use can lead to physical dependence and difficult withdrawal. This review examines evidence for current and novel strategies to manage benzodiazepine withdrawal symptoms.

Keywords:
AbuseBenzodiazepinesCircadinClinical risksDependenceFlumazenilWithdrawal

More Related Videos

Elevated Plus Maze Test Combined with Video Tracking Software to Investigate the Anxiolytic Effect of Exogenous Ketogenic Supplements
05:42

Elevated Plus Maze Test Combined with Video Tracking Software to Investigate the Anxiolytic Effect of Exogenous Ketogenic Supplements

Published on: January 7, 2019

33.0K
Behavioral Disturbances: An Innovative Approach to Monitor the Modulatory Effects of a Nutraceutical Diet
07:05

Behavioral Disturbances: An Innovative Approach to Monitor the Modulatory Effects of a Nutraceutical Diet

Published on: January 3, 2017

9.4K

Related Experiment Videos

Last Updated: Mar 27, 2026

A Novel Method of Drug Administration to Multiple Zebrafish Danio rerio and the Quantification of Withdrawal
10:52

A Novel Method of Drug Administration to Multiple Zebrafish Danio rerio and the Quantification of Withdrawal

Published on: November 12, 2014

12.7K
Elevated Plus Maze Test Combined with Video Tracking Software to Investigate the Anxiolytic Effect of Exogenous Ketogenic Supplements
05:42

Elevated Plus Maze Test Combined with Video Tracking Software to Investigate the Anxiolytic Effect of Exogenous Ketogenic Supplements

Published on: January 7, 2019

33.0K
Behavioral Disturbances: An Innovative Approach to Monitor the Modulatory Effects of a Nutraceutical Diet
07:05

Behavioral Disturbances: An Innovative Approach to Monitor the Modulatory Effects of a Nutraceutical Diet

Published on: January 3, 2017

9.4K

Area of Science:

  • Pharmacology
  • Psychiatry
  • Clinical Medicine

Background:

  • Benzodiazepines, CNS-depressant medications, are widely used for anxiety disorders.
  • 20-30% of long-term users develop physical dependence, with withdrawal issues recognized since the 1980s.
  • Cessation can cause significant physical and psychological withdrawal symptoms, even with slow tapering.

Purpose of the Study:

  • To review the evidence for the effectiveness of standard and emerging treatments for benzodiazepine withdrawal.
  • To analyze the efficacy of current management strategies and novel pharmacological agents.
  • To identify optimal withdrawal schedules and interventions for benzodiazepine dependence.

Main Methods:

  • Systematic review of existing literature on benzodiazepine withdrawal.
  • Analysis of studies evaluating standard slow tapering with psychotherapy.
  • Examination of evidence for pharmacological aids like SSRIs, flumazenil, and melatonin.

Main Results:

  • Limited evidence supports specific optimal withdrawal schedules beyond general drug withdrawal principles.
  • Standard management involves slow tapering over weeks/months, often with psychotherapy.
  • Antidepressants (SSRIs) may help with co-occurring depressive symptoms; flumazenil and melatonin show experimental promise.

Conclusions:

  • Current evidence for optimal benzodiazepine withdrawal is limited, relying on established drug cessation principles.
  • Psychotherapy and slow tapering remain the cornerstone of management.
  • Further research is needed to validate newer agents and refine withdrawal protocols for improved patient outcomes.